Reuters: Did the Neurontin Lawsuit Fuel Health Spending?
In 2004, Pfizer, the world's largest drug company, agreed to plead guilty and pay more than $430 million to settle charges it had illegally marketed the epilepsy drug Neurontin for unapproved uses. Now, a study in the Journal of Clinical Psychiatry questions whether the lawsuit ended up fueling spending on other epilepsy drugs instead of curbing so-called off-label prescribing (Joelving, 10/26).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.